SCHEMBL1033103

SCHEMBL1033103

CCC(=O)N1CCC(c2ccccc2)=N1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
ALDH1A1 P00352 2/20 0.70
HPGD P15428 1/20 0.70
HCRTR1 O43613 1/20 0.56
PGR P06401 5/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
POLB P06746 1/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
NPC1 O15118 4/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GLA P06280 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981651 0.83 ALDH1A1 (0.50) RAB9ASMN1; SMN2ALDH1A1HPGDHCRTR1
SCHEMBL25976340 0.80 ALDH1A1 (0.47) RAB9ASMN1; SMN2ALDH1A1HPGDHCRTR1
SCHEMBL9234149 0.79 PGR (0.50) RAB9ASMN1; SMN2ALDH1A1HPGDHCRTR1
SCHEMBL982457 0.79 MAOB (0.49) RAB9ASMN1; SMN2ALDH1A1HPGDHCRTR1
SCHEMBL980240 0.77 MAOB (0.53) RAB9ASMN1; SMN2ALDH1A1HPGDHCRTR1
SCHEMBL982974 0.76 RAB9A (0.58) RAB9ASMN1; SMN2ALDH1A1HPGDHCRTR1
SCHEMBL979242 0.75 ALDH1A1 (0.56) RAB9ASMN1; SMN2ALDH1A1HPGDHCRTR1
SCHEMBL12922889 0.75 MAOB (0.50) RAB9ASMN1; SMN2ALDH1A1HPGDHCRTR1
SCHEMBL981780 0.74 ALDH1A1 (0.48) RAB9ASMN1; SMN2ALDH1A1HPGDHCRTR1
SCHEMBL979286 0.74 ALDH1A1 (0.71) RAB9ASMN1; SMN2ALDH1A1HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US disclosed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 RAB9A 2347/4885SMN1; SMN2 4245/4885ALDH1A1 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.